Skip to content

Research on Bladder Cancer Treatment Efficacy Evaluation Using Integrated Pathology and Radiomics Model

Research on Bladder Cancer Treatment Efficacy Evaluation Using Integrated Pathology and Radiomics Model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112286
Enrollment
Unknown
Registered
2025-11-12
Start date
2025-11-30
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Interventions

Sponsors

The Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Pathologically confirmed bladder cancer patients; (2) Pelvic contrast-enhanced CT or MRI scans performed within 20 days prior to surgery; (3) Complete clinical and pathological data; (4) Availability of clear HE-stained sections.

Exclusion criteria

Exclusion criteria: (1) Incomplete clinical data; (2) Poor quality of imaging or pathological images; (3) Unclear lesion margins; (4) Presence of other malignant tumors; (5) Received chemotherapy, radiotherapy, or immunotherapy prior to imaging examination.

Design outcomes

Primary

MeasureTime frame
Area Under the Receiver Operating Characteristic Curve ;

Secondary

MeasureTime frame
Sensitivity;Specificity;

Countries

China

Contacts

Public ContactWang Hexiang

Department of Radiology, The Affiliated Hospital of Qingdao University

17853299958@163.com+86 178 5329 9958

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026